Omeros Corp. (OMER) announced Thursday that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 or MASP-2 program.
The first clinical trial with OMS721 will be conducted in Europe and will evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of OMS721 administered subcutaneously in healthy subjects, the company said.
The company stated that it plans to follow this study with a clinical trial evaluating OMS721 in patients with atypical hemolytic uremic syndrome (aHUS), a rare but life-threatening form of thrombotic microangiopathy or TMA. Enrollment in the initial clinical trial is scheduled to begin next month.
The company noted that it has filed for orphan drug designation in the United States for the use of OMS721 to treat aHUS and will request orphan drug designation in Europe as well. Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2.
OMS721 selectively inhibits MASP-2, a novel pro-inflammatory protein involved in activation of the complement system, which is an important component of the immune system and plays a role in the inflammatory response to tissue damage or microbial infection. By selectively inhibiting MASP-2, OMS721 blocks the lectin pathway of the complement system while leaving intact the classical pathway, which represents the acquired immune response to infection.
The company said its previously reported preclinical findings indicate that blockade of MASP-2 by OMS721 may have a preventive or therapeutic effect in the treatment of aHUS and other life-threatening TMAs, such as hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, as well as a wide range of additional disorders, including age-related macular degeneration, ischemia-reperfusion injury and transplant-related complications.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.